Thermo Fisher Scientific Collaborates with TransMIT GmbH on a High-Performance Orbitrap Mass Spectrometry Imaging Platform

Co-marketing agreement between Thermo Fisher Scientific and TransMIT allows for high spatial and high mass resolution MSI platform to study complex biological tissues

MINNEAPOLIS--(BUSINESS WIRE)--ASMS 2022 - Thermo Fisher Scientific Inc., the world leader in serving science, and TransMIT GmbH Center for Mass Spectrometric Developments have announced a co-marketing agreement to promote the use of a mass spectrometry imaging (MSI) platform for spatial multi-omics applications in pharma and clinical labs.

As part of the relationship, TransMIT will combine its proprietary scanning microprobe matrix-assisted laser desorption/ionization (SMALDI) MSI and 3D-surface MSI technology with the exceptional high resolution accurate mass (HRAM) power of Thermo Scientific Orbitrap MS instrumentation. TransMIT’s AP-SMALDI⁵ AF ion source coupled with Orbitrap MS technology enables spatial distribution mapping of a variety of molecules such as biomarkers, metabolites, peptides or enzymatically-digested proteins by their molecular masses. This approach can be applied to omics applications such as metabolomics, lipidomics, proteomics, glycomics and to pharmaco-kinetic studies in a variety of tissues.

“This co-marketing agreement will provide integrated solutions for mass spectrometry imaging, offering a label-free approach to map the distribution of a wide range of both known and unknown compounds directly sampled from biological tissue,” said Jim Yano, senior director, life sciences mass spectrometry portfolio management, chromatography and mass spectrometry, Thermo Fisher Scientific. “Due to its high performance in spatial resolution, TransMIT’s AP-SMALDI⁵ AF ion source is the perfect match for the high mass resolution and accurate mass capabilities of the Orbitrap MS instrumentation.”

Professor Bernhard Spengler, director, TransMIT Center for Mass Spectrometric Developments, said, “Our AP-SMALDI⁵ AF ion source coupled with Thermo Fisher’s Orbitrap technology create an MSI platform for high spatial resolution along with high mass resolution and mass accuracy. The AP-SMALDI-Orbitrap setup enables scanning of tissue samples or 3D objects with the pulsed laser beam of 5 μm spot size routinely without oversampling, providing a powerful solution for drug development and spatial multi-omics applications.”

Announcement of the new co-marketing agreement coincides with the 70^th American Society for Mass Spectrometry (ASMS) Conference on Mass Spectrometry and Allied Topics, being held June 5-9, 2022 where Thermo Fisher is showcasing its latest innovations in Booth 400 at the Minneapolis Convention Center, Minneapolis, Minnesota and at the Hilton Minneapolis Grand Ballrooms E, F, G.

For more information on the Thermo Fisher solutions exhibited at ASMS 2022, please visit www.thermofisher.com/ASMS.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue of approximately $40 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, increasing productivity in their laboratories, improving patient health through diagnostics or the development and manufacture of life-changing therapies, we are here to support them. Our global team delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon and PPD. For more information, please visit www.thermofisher.com.